Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Amortization of Deferred Charges (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Amortization of Deferred Charges data on record, last reported at $248000.0 in Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges rose 5.98% year-over-year to $248000.0; the TTM value through Sep 2025 reached $972000.0, down 15.92%, while the annual FY2024 figure was $1.1 million, 17.79% down from the prior year.
  • Amortization of Deferred Charges reached $248000.0 in Q3 2025 per GOSS's latest filing, up from $245000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $352000.0 in Q1 2023 and bottomed at $234000.0 in Q3 2024.
  • Average Amortization of Deferred Charges over 4 years is $286933.3, with a median of $293000.0 recorded in 2024.
  • Peak YoY movement for Amortization of Deferred Charges: grew 20.55% in 2023, then dropped 27.55% in 2024.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $270000.0 in 2022, then increased by 14.07% to $308000.0 in 2023, then dropped by 22.73% to $238000.0 in 2024, then rose by 4.2% to $248000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $248000.0 in Q3 2025, $245000.0 in Q2 2025, and $241000.0 in Q1 2025.